Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105

Journal of Clinical Oncology

Volumn 28, Issue 23, 2010, Pages 3739-3745

  Yamamoto, Nobuyuki ^a   Nakagawa, Kazuhiko ^a   Nishimura, Yasumasa ^a   Tsujino, Kayoko ^a   Satouchi, Miyako ^a   Kudo, Shinzoh ^a   Hida, Toyoaki ^a   Kawahara, Masaaki ^a   Takeda, Koji ^a   Katakami, Nobuyuki ^a   Sawa, Toshiyuki ^a   Yokota, Soichiro ^a   Seto, Takashi ^a   Imamura, Fumio ^a   Saka, Hideo ^a   Iwamoto, Yasuo ^a   Semba, Hiroshi ^a   Chiba, Yasutaka ^a   Uejima, Hisao ^a   Fukuoka, Masahiro ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; IRINOTECAN; MITOMYCIN; PACLITAXEL; VINDESINE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DYSPNEA; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; ADJUVANT THERAPY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; LUNG TUMOR; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PHASE 3 CLINICAL TRIAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MITOMYCIN; PACLITAXEL; RADIOTHERAPY, ADJUVANT; VINDESINE;

EID: 77957287051     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.24.5050     Document Type: Article

References (18)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics. Ca Cancer J Clin 57:43-66, 2007
2. van Meerbeeck JP: Staging of non-small cell lung cancer: Consensus, controversies and challenges. Lung Cancer 34:S95-S107, 2001 (suppl 2)
3. Dillman RO, Seagren SL, Propert KJ, et al: A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323:940-945, 1990 (Pubitemid 20332333)
4. Sause W, Kolesar P, Taylor SIV, et al: Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117:358-364, 2000
5. Furuse K, Fukuoka M, Kawahara M, et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692-2699, 1999 (Pubitemid 29415225)
6. Curran WJ, Scott CB, Langer CJ, et al: Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 22:621, 2003 (suppl; abstr 2499)
7. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002 (Pubitemid 34438899)
8. Bunn PA Jr, Kelly K: New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions. Clin Cancer Res 4:1087-1100, 1998
9. Hoffman PC, Mauer AM, Vokes EE: Lung cancer. Lancet 355:479-485, 2000 (Pubitemid 30085163)
10. Movsas B, Hudes RS, Schol J: Induction and concurrent paclitaxel/carboplatin every 3 weeks with thoracic radiotherapy in locally advanced non-small- cell lung cancer: An interim report. Clin Lung Cancer 3:125-132, 2001 (Pubitemid 33138776)
11. Govindan G, Bogart J, Wang X, et al: Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407. J Clin Oncol 27:383s, 2009 (abstr 7505)
12. Vokes EE, Herndon JE 2nd, Crawford J, et al: Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and Leukemia Group B study 9431. J Clin Oncol 20:4191-4198, 2002 (Pubitemid 35191021)
13. Belani CP, Choy H, Bonomi P, et al: Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: A randomized phase II locally advanced multi-modality protocol. J Clin Oncol 23: 5883-5891, 2005
14. Choy H, Akerley W, Safran H, et al: Multi-institutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol 16:3316-3322, 1998 (Pubitemid 28481627)
15. Vokes EE, Herndon JE 2nd, Kelley MJ, et al: Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 25:1698-1704, 2007 (Pubitemid 46797950)
16. Uejima H: Dose-finding study of weekly irinotecan (CPT-11) and carboplatin (CBDCA) with concurrent thoracic radiotherapy (TRT) in locally advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 21:220b, 2002 (abstr 2699)
17. Endo M, Takada Y, Obayashi K, et al: Weekly paclitaxel and carboplatin with concurrent radiation therapy in locally advanced non-small cell lung cancer: Phase I study. Radiat Med 23:331-335, 2005 (Pubitemid 41265351)
18. Hanna N, Neubauer M, Yiannoutsos C, et al: Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non- small-cell lung cancer: The Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 26:5755-5760, 2008